Bio-Techne
Prezzo: 54.00Società e modello di business
Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.
Profilo di investimento
The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 0.71 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 5.3% ↑
- Sorpresa EPS
- -3.6% in linea
- Volatilità 20g
- 2.8% stabile
- Rendimento dividendo
- 0.6% basso ultima data ex-dividendo: 2026-05-18
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-05 02:49 | Vendi | Mantieni | Mixed performance; cautious outlook due to volatility. |
| 2026-05-30 02:52 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:11 | — | Mantieni | Weak fundamentals and negative momentum raise significant concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-11 09:52 | Piper Sandler | Aggiorna | — → 65 | 52.5 |
| 2026-05-14 20:21 | RBC Capital | Aggiorna | — → 62 | 44.74 |
| 2026-05-07 12:07 | Evercore ISI | Target abbassato | 54 → 50 | 49.265 |
Ancora nulla